Research Article
Prognostic Factor Study of Macular Edema Recurrence in Retinal Vein Occlusion after Conbercept Treatment: A Post Hoc Analysis of the FALCON Study

Haiying Zhou,1 Zuhua Sun,2 Meng Zhao,1 Xiaoling Liu,2 Xuan Jiao,1 Weiwei Zheng,2 and Feng Zhang1

1Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing 100730, China
2Department of Retina, The Affiliated Eye Hospital, Wenzhou Medical University, Wenzhou, China

Correspondence should be addressed to Feng Zhang; zhangfeng@mail.ccmu.edu.cn

Received 4 May 2022; Revised 4 July 2022; Accepted 13 July 2022; Published 29 July 2022

Academic Editor: Min Tang

Copyright © 2022 Haiying Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The study was aimed at exploring the potential predictive factors associated with the recurrence of macular edema (ME) secondary to vein occlusion (RVO) after intravitreal antivascular endothelial growth factor (VEGF) loading treatment in the FALCON study. Methods. This is a post hoc analysis of 30 patients with central RVO and 30 patients with branch RVO. All patients received a monthly administration of intravitreal conbercept during the 3-month loading phase and pro re nata (PRN) treatment during the 6-month follow-up period. Based on the recurrence of ME at the first follow-up visit, patients were classified into the recurrence group or nonrecurrence group. The primary endpoint was to explore the risk factors for recurrence among baseline characteristics, fluorescein angiography (FA) patterns, and optical coherence tomography (OCT). Results. In general, 38 patients (64.4%) experienced ME recurrence at the first follow-up visit (3 months), regardless of disease type \( (p = 0.32) \). Significant improvements in VA were noted in both the nonrecurrence and recurrence groups \( (p < 0.001) \), however, without significant between-group differences \( (p = 0.1) \). A significant reduction in CRT in both groups \( (p < 0.001) \) was identified, and patients without recurrence showed a greater reduction in CRT compared with those with recurrence \( (p < 0.001) \). In addition, logistic regression analyses indicated the corrections of ME recurrence with baseline macular volume and the disruption of the outer limiting membrane at the fovea. Conclusion. This study suggested that OCT parameters, including baseline macular volume and outer limiting membrane disruption, and reduction in CRT after loading therapy were more predictive of ME recurrence than FA patterns or visual changes following conbercept loading therapy.

1. Introduction
Retinal vein occlusion (RVO) obstructs the retinal veins [1] and is the second most common retinal vascular disease after diabetic retinopathy [2]. In general, RVO is commonly divided into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) [1]. Thrombosis of the retinal veins increases retinal capillary pressure, capillary permeability, and leakage of fluid and blood into the retina [3, 4]. In patients with RVO, macular edema (ME) is the most common complication and the principal cause of visual impairment [5]. The overproduction of vascular endothelial growth factor (VEGF) is a major cause of the development of ME and hemorrhages [6]. Furthermore, high levels of VEGF promote the progression of retinal nonperfusion and ischemia, which in turn can lead to increased VEGF levels [7], worsening ME and hemorrhages and resulting in subsequent visual impairment. Thus, intravitreal therapy with anti-VEGF is increasingly used to treat ME in patients with RVO [8].

ME is visible on the fundus as increased macular thickness, fluid, or exudates. Fluorescein angiography (FA) can reveal vascular leakage and filling of cystic spaces [9, 10]. However, the gold standard for diagnosing and evaluating
ME due to RVO is optical coherence tomography (OCT), a noninvasive imaging tool for macular lesions [11, 12]. Furthermore, central retinal thickness (CRT) is a measure derived from OCT scans and is an essential outcome in clinical trials to assess drug efficacy and vision outcomes [13]. Previous studies have identified the corrections between CRT and visual outcomes after administration of anti-VEGF therapy in patients with ME due to RVO [14, 15].

Conbercept (Lumitin; Chengdu Kang Hong Biotech Co., Ltd., Sichuan, China) is a recombinant fusion protein composed of the extracellular domain 2 of VEGF receptor 1 (VEGFR1) and extracellular domains 3 and 4 of VEGFR2 to the constant region (Fc) of human immunoglobulin G1. This drug binds specifically to various isoforms of VEGF-A, VEGF-B, and placental growth factors [16]. Previous clinical trials noted significant clinical benefits with conbercept in patients suffering from age-related macular degeneration, pathological myopia-associated choroidal neovascularization, or diabetic macular edema (DME) [17–19]. Furthermore, conbercept demonstrated high efficacy and a favorable safety profile in ME secondary to RVO in the phase II FALCON study [20].

Although the efficacy and safety of conbercept were identified previously, there is a lack of investigations on the prognostic factors of ME recurrence after administration of intravitreal anti-VEGF. Thus, we conducted this study to evaluate the association between baseline characteristics, FA patterns, and OCT parameters on ME recurrence after treatment with three consecutive loading doses of conbercept.

2. Methods

The data used in this post hoc analysis were obtained during the FALCON study (NCT01809236) [20]. It was a phase II, nonrandomized, noncontrolled, 9-month trial in China to assess the efficacy and safety of intravitreal conbercept in ME secondary to RVO. Patients were recruited from two sites in China, such as the Affiliated Eye Hospital of Wenzhou Medical University and Beijing Tongren Hospital, affiliated to Capital Medical University in China. The study subjects used in this analysis were collected between September 2012 and May 2014. The study complied with the Helsinki Declaration and Good Clinical Practice Guidelines. Each institution’s institutional review boards and ethics committee approved the study protocol. All patients provided written informed consent before enrolling in the study.

2.1. Participants. The inclusion criteria were as follows: (1) patients were aged 18 years or older; (2) patients had central ME secondary to BRVO or CRVO that had occurred within the past six months; and (3) those had a best-corrected visual acuity (BCVA) of ≥20/40 Snellen equivalent) and a CRT of ≥250 μm as measured by spectral-domain OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany). We defined CRVO as an RVO involving four retinal quadrants and BRVO by retinal hemorrhages or other biomicroscopic evidence of RVO and a dilated venous system in two or fewer quadrants of the retina drained by the affected vein. One eye per individual was included in this study.

The exclusion criteria included a relative afferent pupillary defect, prior vitreoretinal surgery, intravitreal anti-VEGF (including but not limited to ranibizumab or bevacizumab) in the study eye within the past six months or in the fellow eye within the past three months, systemic treatment of any anti-VEGF within six months, intraocular or pericircular steroid treatment in the study eye within the past three months or systemic steroids within the past one month, reductions in visual acuity from any causes other than RVO, ocular inflammation in either eye, uncontrolled glaucoma (intraocular pressure ≥ 25 mmHg or history of filtration surgery), or treatments using scatter or pan-retinal laser, macular grid laser, or sector laser in the study eye.

2.2. Treatment Protocol. A total of 60 patients from the FALCON study in the current research, including 30 ones with BRVO and 30 ones with CRVO. All patients received an administration of intravitreal conbercept (0.5 mg) every month during the loading phase of 3 months. After the loading phase, all patients were followed up monthly for six months. Patients with an increase in CRT by ≥50 μm as compared with the lowest measured value; a loss of ≥5 ETDRS letters compared with the most recent measurement; the presence of new or persistent cystic retinal changes, subretinal fluid (SRF), or neuroepithelial detachment; or the presence of new macular hemorrhage, retinal neovascularization, or any new BRVO received subsequent injections as needed (pro re nata; PRN).

2.3. Outcome Measures. The total follow-up time was up to 9 months. Based on the recurrence of ME at the first follow-up visit, all patients were classified into the recurrence group or nonrecurrence group. The primary outcomes were differences between the two groups and risk factors for recurrence among baseline characteristics, FA patterns, and OCT parameters.

We recorded the following data at baseline: (1) demographics; (2) BCVA; (3) intraocular pressure; (4) findings of fundus photography including bleeding and hard exudation in the macular area (Topcon TRC.50-DX; Topcon, Japan); and (5) OCT (HRA-II, Heidelberg, Germany) including CRT, macular volume (MV), ellipsoid zone (EZ), outer limiting membrane (OLM), disorganization of inner retinal layers (DRIL), SRF, and intraretinal fluid; OCT was measured by mean changes in foveal retinal thickness at all visits (1-9 months) compared with baseline, percentage of subjects with foveal retinal thickness ≤ 250 μm compared with baseline at 3 and 9 months after treatment, and changes in macular edema volume compared with baseline at all visits (months 1-9). (6) Findings of fluorescence angiography (HRA-II, Heidelberg, Germany) include foveal avascular zone contours, nonperfusion area (NPA), and macular hemorrhage. We assessed BCVA following the ETDRS protocol [21]. Data were collected during the follow-up period using BCVA, FP, and OCT. In order to standardize the reading of Falcon test and ensure the reading quality, each center has carried out cross reading of OCT, FA, and CFP images.
2.4. Statistical Analyses. All data were analyzed using R software (version 3.2.0). Continuous variables are presented as medians with interquartile range (IQR). Person count and percentages describe categorical variables. We compared the baseline ocular characteristics between the two groups, and those characteristics with a p value less than 0.3 were included in a binary backward stepwise logistic regression model. We excluded insignificant predictor variables if the Akaike information criterion of the model including this variable was higher when the predictor was not included.

To compare visual acuity and CRT changes between the two groups, we used repeated-measurement analysis of variance and calculated the odds ratio (OR) and its 95% confidence interval (CI). All statistical tests were two-sided. A p value of <0.05 was considered statistically significant.

3. Results

Among the study subjects, the mean age was 56.7 years, and 33 (55.0%) were male while 30 were diagnosed with CRVO and 30 with BRVO. The median time to onset of disease was 3 months (range, 2–5). Over the 9 months, the total mean number of injections was 7.59 ± 1.39 for CRVO and 7.14 ± 1.90 for BRVO.

At baseline, as compared with patients with BRVO, patients with CRVO showed significantly poorer vision (BCVA [ETDRS letters], 48.73 ± 15.9 in CRVO vs. 57.83 ± 13.42 in BRVO, p = 0.02), a higher CRT (695.5 μm [IQR, 592-916] in CRVO vs. 549.5 μm [IQR, 467-656] in BRVO, p = 0.0002), a larger MV (13.79 mm³ [IQR, 11.81-17.41] in CRVO vs. 12.35 mm³ [IQR, 11.27-13.85] in BRVO, p = 0.015), a smaller area of macular NPA (p = 0.0007), a lower proportion of macular hemorrhage (66.7% vs. 96.7%, p = 0.006), and a higher proportion of cystoid macular edema (CME; 96.7% vs. 53.3%; Table 1).

One patient with CRVO was lost to follow-up one month after the loading phase and was, therefore, not included in the subsequent analysis. When we compared the baseline BCVA to that at the first follow-up visit, we considered a gain of ≥15 ETDRS letters from baseline as an improvement, <15 letters as vision maintenance, and a loss of ≥15 ETDRS letters as a worsening disease. Among the patients with CRVO, 12 eyes (41.38%) showed improvement, 16 (55.17%) eyes showed no change, and 1 (3.35%) eye worsened. Among those with BRVO, 17 (56.67%) eyes improved, 13 (43.33%) eyes showed no change, and no eyes worsened. No statistically significant differences were found between the two groups in vision changes. After the loading phase, changes in CRT from baseline were greater for patients with CRVO than for those with BRVO (−339.0 μm [IQR, 219.0] vs. −274.5 μm [IQR, 198.0], p < 0.001). The vision changes between male and female were without statistical difference (14.0 letters [IQR, 8.0] vs. 10.5 letters [IQR, 12.3], p = 0.10). Neither was found in CRT changes (−307.0 μm [IQR, 259.0] vs. −298.5 μm [IQR, 142.0], p = 0.34).

After the loading phase, 38 patients (63.3%) experienced ME recurrence and required redosing at the first visit after the loading phase. Among these, 17 patients (56.7%) had BRVO and 21 (70%) had CRVO, and the recurrence was independent of disease type (p = 0.32). Among the patients who received redosing, the BCVA at baseline, last examination during the loading phase, and first follow-up visit were 57 letters (IQR, 11), 72 letters (IQR, 12), and 74 letters (IQR, 13), respectively. For those who had not yet needed additional injections, the BCVA at baseline, last examination during the loading phase, and first follow-up visit were 59 letters (IQR, 25), 69 letters (IQR, 27), and 71.5 letters (IQR, 27.8), respectively. However, there were significant improvements in vision in both groups (p < 0.001) and no significant differences among groups (Figure 1(a)). Similarly, CRT was significantly lower in both groups (p < 0.001; Figure 1(b)). However, patients who did not experience recurrence had a greater CRT reduction than those who received redosing (p < 0.001; Figure 2).

In this study, the baseline MV significantly correlated with the recurrence of ME at the first visit after the loading phase (OR = 1.44, 95% CI, 1.08–1.92; p = 0.01; Table 2). In addition, a significant correlation between the presence of disrupted OLM at the fovea and recurrence of ME was identified (OR = 0.17, 95% CI 0.05–0.64; p = 0.008). We detected no significant association between ME recurrence and FA patterns, including irregular FAZ contours, NPA, or macular hemorrhage (Table 2). Patients who required redosing showed a trend toward a higher baseline CRT as compared with patients who did not yet require additional doses (634.5 μm [IQR, 206.2] vs. 573.0 μm [IQR, 195.0], p = 0.07, Table 2). Because the CRT and MV can be confounding variables and because we established a linear correlation between CRT and MV in this study (p < 0.001, R² = 0.75), we used the baseline MV instead of the CRT as the independent variable in the multinomial regression analyses to determine the correlations with ME recurrence. These factors were subjected to logistic regression analysis. In this model, the Akaike information criterion was 68.5, and the area under the curve was 0.789 (Figure 3).

4. Discussion

Previous studies demonstrated the efficacy and safety of intravitreal injection of conbercept to treat ME secondary to RVO. Such clinical benefits consistently improved visual acuity and anatomic endpoints in both BRVO and CRVO groups. In the FALCON study, these improvements persisted and even improved with PRN dosing during the follow-up period [20]. However, in that study, the response to conbercept treatment varied among individuals in patients with ME secondary to RVO. After the loading phase, ME persisted in some eyes, and subsequent injections were required. Among the patients who experienced a ME
resolution, some experienced ME recurrence and required repeated injections. Because the prediction of ME recurrence is clinically essential for long-term outcomes in patients with ME secondary to RVO, this post hoc study to identify predictive factors associated with ME recurrence was conducted. Baseline characteristics and related data at the first follow-up visit from the FALCON study were collected and analyzed. Considering that a similar proportion of patients with BRVO and CRVO received PRN dosing after the loading phase, we included patients with both BRVO and CRVO in this study.

OCT is one of the most common imaging modalities for assessing the efficacy of therapeutics in ME secondary to RVO [22]. The CRUISE and BRAVO studies reported a rapid reduction in CRT within one week after ranibizumab treatment. The mean CRT reduction from baseline to 6 months was $-339 \, \mu m \ (0.3 \, mg)$ and $-345 \, \mu m \ (0.5 \, mg)$ in CRVO patients and $-339 \, \mu m \ (0.3 \, mg)$ and $-345 \, \mu m \ (0.5 \, mg)$ in BRVO patients, respectively [23, 24]. In the BRAVO study, OCT images at month 3 of ranibizumab treatment provided predictive information for patients with CRVO but not for those with BRVO [25]. In particular, poorer vision outcomes at 6 and 12 months were associated with persistent CME and a central foveal thickness of $\geq 250 \, \mu m$ at 3 months. Our study found a significant reduction in CRT and an improvement in VA in both groups after the loading phase. At the first follow-up visit, changes in CRT from baseline were $-339.0 \, \mu m$ in CRVO patients and $-274.5 \, \mu m$ in BRVO patients. Concomitantly, a VA gain of $\geq 15$ ETDRS letters was achieved in 41.38% of patients with CRVO and in 56.67% of patients with BRVO.

Several studies have investigated the OCT parameters related to ME recurrence. For example, in eyes with BRVO, cystic macular changes and DRIL with ME recurrence were

---

**Table 1: Baseline characteristics of the study subjects.**

| Features                              | CRVO ($n = 30$) | BRVO ($n = 30$) | p value |
|---------------------------------------|-----------------|-----------------|---------|
| Mean BCVA (ETDRS letters)             | 48.73 ± 15.91   | 57.83 ± 13.42   | 0.02    |
| CRT (median, IQR)                     | 695.5 (592–916) | 549.5 (467–656) | 0.0002  |
| MV (median, IQR)                      | 13.79 (11.81–17.41) | 12.35 (11.27–13.85) | 0.015   |
| Regular FAZ contours $^1$, n (%)      | 15 (50.0%)      | 8 (26.7%)       | 0.07    |
| Nonperfusion area (NPA)$^2$           |                 |                 | 0.0007  |
| No NP, n (%)                          | 13 (43.33%)     | 1 (3.33%)       |         |
| $<5$ PD, n (%)                        | 5 (16.67%)      | 8 (26.67%)      |         |
| $>5$ PD, n (%)                        | 9 (30.00%)      | 17 (56.67%)     |         |
| Macular hemorrhage, n (%)             | 20 (66.67%)     | 29 (96.67%)     | 0.006   |
| Macular HE, n (%)                     | 3 (10.00%)      | 7 (23.33%)      | 0.3     |
| Intact, n (%)                         | 5 (16.67%)      | 8 (26.67%)      |         |
| Disruption in the fovea, n (%)        | 13 (43.33%)     | 15 (50.00%)     |         |
| Disruption in the parafovea, n (%)    | 2 (6.67%)       | 4 (13.33%)      |         |
| Unevaluable, n (%)                    | 10 (33.33%)     | 3 (10.00%)      |         |
| OLM                                   |                 |                 | 0.86    |
| Intact, n (%)                         | 8 (26.67%)      | 8 (26.67%)      |         |
| Disruption in the fovea, n (%)        | 10 (33.33%)     | 14 (46.67%)     |         |
| Disruption in the parafovea, n (%)    | 3 (10.00%)      | 5 (16.67%)      |         |
| Unevaluable, n (%)                    | 9 (30.00%)      | 3 (10.00%)      |         |
| DRIL$^3$, n (%)                       | 10 (33.33%)     | 11 (36.67%)     | 0.99    |
| IRF                                   |                 |                 | 0.0004  |
| No IRF, n (%)                         | 0 (0.00%)       | 1 (3.33%)       |         |
| Macula area, n (%)                    | 1 (3.33%)       | 10 (33.33%)     |         |
| Paramacular area, n (%)               | 0 (0.00%)       | 3 (10.00%)      |         |
| CME, n (%)                            | 29 (96.67%)     | 16 (53.33%)     |         |
| SRF                                   |                 |                 | 0.73    |
| No SRF, n (%)                         | 10 (33.33%)     | 8 (26.67%)      |         |
| Small amount, n (%)                   | 16 (53.33%)     | 16 (53.33%)     |         |
| Large amount, n (%)                   | 4 (13.33%)      | 6 (20.00%)      |         |

$^1$Two unevaluable patients were not included in the analysis. $^2$Six patients with bleeding events were not included. $^3$Six patients with unevaluable DRIL were not included. SD: standard deviation; IQR: interquartile range; BCVA: best-corrected visual acuity; CRT: central retina thickness; MV: macular volume; FAZ: foveal avascular zone; NPA: nonperfusion area; PD: papilla diameter; HE: hard exudates; EZ: ellipsoid zone; OLM: outer limiting membrane; DRIL: disorganization of retinal inner layers; IRF: intraretinal fluid; CME: cystoid macular edema; SRF: subretinal fluid.
Although the baseline CRT was not significantly related to ME recurrence ($p = 0.07$) in our study, patients without recurrence had a greater reduction in CRT than those with recurrence after loading therapy ($p < 0.001$). Moreover, logistic regression analysis showed that the baseline MV significantly correlated with ME recurrence at the first visit after the loading phase. Because MV is a more comprehensive ME indicator than CRT especially for the perifoveal regions, MV can be adopted as a prognostic factor for ME secondary to RVO. In addition, because we established a linear correlation between CRT and MV in this study, CRT could be a confounding variable to MV in ME prognosis. Notably, for subanalysis, no significant differences were identified between genders.

In addition to measuring the central foveal thickening of the macula edema, the OCT system allows the microretinal structures to be visualized, including the OLM and EZ. In particular, previous studies identified the correction of disruption in the OLM with poor visual prognosis after RVO treatment [29–32]. However, in a recent study that collected and analyzed the data of 381/301 BRVO/CRVO naive patients from the BRIGHTER and CRYSTAL studies, only...
CRT and age were associated with visual prognosis instead of OLM disruption or DRIL [15]. In our study, we noted a significant correlation between baseline OLM disruption at the fovea and ME recurrence, suggesting that baseline OLM integrity could serve as a predictor for recurrence of ME. The OLM is a linear confluence of junctional complexes between Muller cells and photoreceptors [33]. In addition, the OLM separates the layers of rods and cones from the overlying outer nuclear layer and serves as a barrier against macromolecules [34]. A prior study demonstrated the presence of tight junctions (TJs) in the OLM and between the glial Muller cells and photoreceptors in rat and monkey retinas [35]. Occludin, an integral membrane protein that localizes at the TJ [36], was organized between the glial Muller cells and the photoreceptors. Occludin expression decreased, and glial Muller cells swelled in DME at the OLM level [37]. These findings suggest that the OLM could be a part of the retinal barrier, and its disruption could result in fluid retention and consequent edema. Although anti-VEGF treatment can restore the barrier effect of the OLM [38, 39], recurrent episodes of edema occur when baseline damage to the OLM is too severe to be restored.

### Table 2: Clinical measurements comparisons of the study eyes between the recurrence group and nonrecurrence group.

| Features                        | Recurrence group (n = 38) | Nonrecurrence group (n = 21) | p value |
|---------------------------------|---------------------------|-----------------------------|---------|
| **Features**                    |                           |                             |         |
| **Disease type**                |                           |                             |         |
| BRVO, n (%)                     | 17 (44.74%)               | 13 (61.90%)                 | 0.32    |
| CRVO, n (%)                     | 21 (55.26%)               | 8 (38.10%)                  |         |
| **BCVA (ETDRS letters), median (IQR)** | 59 (25)                  | 57 (11)                     | 0.32    |
| **CRT, median (IQR)**           | 634.5 (207)               | 573.0 (195)                 | 0.07    |
| **MV, median (IQR)**            | 13.04 (4.41)              | 11.41 (3.25)                | 0.01    |
| **Irregular FAZ contours, n (%)** | 24 (63.16%)              | 11 (52.38%)                 | 0.75    |
| **NP**                          |                           |                             |         |
| No NP, n (%)                    | 10 (26.32%)               | 4 (19.05%)                  | 0.003   |
| <5 PD, n (%)                    | 7 (18.42%)                | 6 (28.57%)                  | 0.18    |
| >5 PD, n (%)                    | 16 (42.11%)               | 10 (47.62%)                 | 0.003   |
| Unevaluable, n (%)              | 5 (13.16%)                | 1 (4.76%)                   | 0.47    |
| **Macular hemorrhage, n (%)**   | 8 (21.05%)                | 2 (9.52%)                   | 0.47    |
| **EZ**                          |                           |                             |         |
| Intact, n (%)                   | 8 (21.05%)                | 5 (23.81%)                  | 0.999   |
| Disruption in the fovea, n (%)  | 14 (36.84%)               | 14 (66.67%)                 | 0.03    |
| Disruption in the parafovea, n (%) | 5 (13.16%)              | 1 (4.76%)                   | 0.41    |
| Unevaluable, n (%)              | 11 (28.95%)               | 1 (4.76%)                   | 0.04    |
| **DRIL**                        |                           |                             |         |
| No, n (%)                       | 19 (50.00%)               | 14 (66.67%)                 | 0.27    |
| Yes, n (%)                      | 15 (39.47%)               | 5 (23.81%)                  | <0.001  |
| Unevaluable, n (%)              | 4 (10.53%)                | 2 (9.52%)                   | 0.99    |
| **OLM**                         |                           |                             |         |
| Intact, n (%)                   | 10 (26.32%)               | 6 (28.57%)                  | 0.99    |
| Disruption in the fovea, n (%)  | 11 (28.95%)               | 13 (61.90%)                 | 0.02    |
| Disruption in the parafovea, n (%) | 7 (18.42%)              | 1 (4.76%)                   | 0.23    |
| Unevaluable, n (%)              | 10 (26.32%)               | 1 (4.76%)                   | 0.08    |
| **IRF**                         |                           |                             |         |
| No IRF, n (%)                   | 0 (0%)                    | 1 (4.76%)                   | 0.36    |
| Macula area, n (%)              | 5 (13.16%)                | 6 (28.57%)                  | 0.17    |
| Paramacular area, n (%)         | 2 (5.26%)                 | 1 (4.76%)                   | 0.99    |
| CME, n (%)                      | 31 (81.58%)               | 13 (61.90%)                 | 0.12    |
| **SRF**                         |                           |                             |         |
| No SRF, n (%)                   | 11 (28.95%)               | 7 (33.33%)                  | 0.77    |
| Small amount, n (%)             | 21 (55.26%)               | 11 (52.38%)                 | 0.99    |
| Large amount, n (%)             | 6 (15.79%)                | 3 (14.29%)                  | 0.99    |

IQR: interquartile range; BCVA: best-corrected visual acuity; CRT: central retina thickness; MV: macular volume; FAZ: foveal avascular zone; NPA: nonperfusion area; PD: papilla diameter; HE: hard exudates; EZ: ellipsoid zone; OLM: outer limiting membrane; DRIL: disorganization of retinal inner layers; IRF: intraretinal fluid; CME: cystoid macular edema; SRF: subretinal fluid.
 Clinically, FA remains an essential tool for detecting morphologic changes in the retinal vasculature and provides a functional evaluation of the extent of macular ischemia, vascular leakage, and neovascularization [11]. As reported by the SCORE study, in patients with BRVO, nonperfusion was the only significant baseline factor for neovascularization [40].

The WAVE study revealed a relationship between retinal ischemia and ME severity, as reflected by central macular thickness [41]. In addition, the correlation between FA patterns and ME recurrence was also investigated. According to a previous study, the central NPA and parafoveal NPA of the superficial capillary plexus strongly correlated with ME recurrence in BRVO patients who received intravitreal anti-VEGF treatment [42]. Similarly, BRVO patients with NPA of more than half of the 1 mm zone of the ETDRS should be monitored closely for ME recurrence within six months of intravitreal bevacizumab injection [43]. Furthermore, patients with BRVO who have significant nonperfusion may require repeated dosing of dexamethasone [44]. Given these, we investigated the relationship between baseline FA patterns and the early recurrence of ME after loading treatment with conbercept. Interestingly, neither the NPA nor macular hemorrhage was associated with ME recurrence at the first follow-up visit. Although this preliminary finding did not support the predictive value of FA in the early recurrence of ME, a longer follow-up period and a larger sample size are required to further evaluate its prognostic value in VA outcomes.

However, this study has several inherent limitations, such as a small cohort size, a lack of long-term data to rule out the possibility of MV remission after four injections, and a lack of systemic collection of baseline characteristics. All of these factors may result in biases and affect the power and significance of the findings. In the future, long-term prospective cohort studies should be conducted to validate the findings and may obtain more study insights.

This study suggests that OCT parameters are more predictive of ME recurrence than FA patterns or visual changes after conbercept loading therapy. Significantly, baseline MV, OLM disruption, and reduction in CRT after anti-VEGF loading therapy could be valuable tools in clinical practice for predicting future recurrence in patients with RVO-related ME.

Data Availability

All the raw data used to support this study are available by contacting the corresponding author upon request.

Conflicts of Interest

The authors have no financial/conflicting interests to disclose.

References

[1] O. Trco, *Retinal vein occlusion (RVO) guidelines*, The Royal College of Ophthalmologists, 2015.
[2] P. A. Campochiaro, W. L. Clark, D. S. Boyer et al., “Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study,” *Ophthalmology*, vol. 122, no. 3, pp. 538–544, 2015.
[3] T. Y. Wong and I. U. Scott, “Retinal-vein occlusion,” *New England Journal of Medicine*, vol. 363, no. 22, pp. 2135–2144, 2010.
[4] T. C. Hsieh, C. L. Chou, J. S. Chen et al., “Risk of mortality and of atherosclerotic events among patients who underwent hemodialysis and subsequently developed retinal vascular occlusion: a Taiwanese retrospective cohort study,” *JAMA Ophthalmology*, vol. 134, no. 2, pp. 196–203, 2016.
[5] S. S. Hayreh, P. A. Podhajsky, and M. B. Zimmerman, “Natural history of visual outcome in central retinal vein occlusion,” *Ophthalmology*, vol. 118, no. 1, pp. 119–133.e2, 2011.
[6] P. A. Campochiaro, G. Hafiz, S. M. Shah et al., “Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator,” *Molecular Therapy*, vol. 16, no. 4, pp. 791–799, 2008.
[7] P. A. Campochiaro, R. B. Bhisitkul, H. Shapiro, and R. G. Rubio, “Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion,” *Ophthalmology*, vol. 120, no. 4, pp. 795–802, 2013.
[8] P. Hykin, A. T. Prevost, J. C. Vasconcelos et al., “Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial,” *JAMA Ophthalmology*, vol. 137, no. 11, pp. 1256–1264, 2019.
[9] A. Arrigo and F. Bandello, “Retinal vein occlusion: drug targets and therapeutic implications,” *Expert Opinion on Therapeutic Targets*, vol. 25, no. 10, pp. 847–864, 2021.
[10] A. A. Aref, I. U. Scott, P. C. VanVeldhuisen et al., “Intraocular pressure-related events after anti-vascular endothelial growth factor therapy for macular edema due to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 report 16 on a secondary analysis of a randomized clinical trial,” *JAMA Ophthalmology*, vol. 139, no. 12, pp. 1285–1291, 2021.
Rubio, the European Society of Retina Specialists (EURETINA), study, conbercept injection for macular edema resulting from central retinal vein occlusion: twelve-month outcomes of a phase III study, vol. 66, no. 1, pp. 20–35, 2018.

R. Tadayoni, S. M. Waldstein, F. Boscia et al., “Macular cystic changes as predictive factor for the recurrence of macular edema in branch retinal vein occlusion,” Acta Ophthalmologica, vol. 95, no. 7, pp. e592–e596, 2017.

H. M. Park, Y. H. Kim, B. R. Lee, and S. J. Ahn, “Topographic patterns of retinal edema in eyes with branch retinal vein occlusion and their association with macular edema recurrence,” Scientific Reports, vol. 11, no. 1, p. 23249, 2021.

M. Suzuki, N. Nagai, S. Minami et al., “Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 258, no. 1, pp. 49–56, 2020.

H. M. Kang, E. J. Chung, Y. M. Kim, and H. J. Koh, “Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion,” Graefe’s Archive For Clinical and Experimental Ophthalmology, vol. 251, no. 2, pp. 501–508, 2013.

U. E. K. Wolf-Schnurrbusch, R. Ghanem, S. P. Rothenbuehler, V. Enzmann, C. Framme, and S. Wolf, “Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion,” Investigative Ophthalmology & Visual Science, vol. 52, no. 6, pp. 3334–3337, 2011.

H. J. Shin, H. Chung, and H. C. Kim, “Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion,” Acta ophthalmologica, vol. 89, no. 1, pp. e35–e40, 2011.

N. Yamaike, A. Tsujikawa, M. Ota et al., “Three-dimensional imaging of cystoid macular edema in retinal vein occlusion,” Ophthalmology, vol. 115, no. 2, pp. 355–362, 2008.

V. J. Srinivasan, B. K. Monson, M. Wojtkowski et al., “Characterization of outer retinal morphology with high-speed, ultrahigh-resolution optical coherence tomography,” Investigative Ophthalmology & Visual Science, vol. 49, no. 4, pp. 1571–1579, 2008.

X.-I. Zhang, L. Wen, Y.-j. Chen, and Y. Zhu, “Vascular endothelial growth factor up-regulates the expression of intracellular adhesion molecule-1 in retinal endothelial cells via reactive oxygen species, but not nitric oxide,” Chinese Medical Journal, vol. 122, no. 3, pp. 338–343, 2009.

T. A. Chowdhury, D. Hopkins, P. M. Dodson, and G. C. Vafidis, “The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?,” Eye, vol. 16, no. 6, pp. 689–693, 2002.

M. Furuse, T. Hirase, M. Itoh et al., “Occludin: a novel integral membrane protein localizing at tight junctions,” The Journal of Cell Biology, vol. 123, no. 6, pp. 1777–1788, 1993.

S. Saxena, L. Akduman, and C. H. Meyer, “External limiting membrane: retinal structural barrier in diabetic macular edema,” International Journal of Retina and Vitreous, vol. 7, no. 1, p. 16, 2021.

N. H. Hareedy, A. A. Gaafar, H. K. Abd El-Dayem, and R. F. A. E.-R. El, “The relation between inner segment/outer segment junction and visual acuity before and after ranibizumab in diabetic macular edema,” Society, vol. 111, no. 3, p. 102, 2018.

N. M. Bressler, “Treatment of macular edema due to central retinal vein occlusion,” Journal of the American Medical Association, vol. 317, no. 20, pp. 2067–2069, 2017.
C. K. Chan, M. S. Ip, P. C. Vanveldhuisen et al., “SCORE study report 11: incidences of neovascular events in eyes with retinal vein occlusion,” *Ophthalmology*, vol. 118, no. 7, pp. 1364–1372, 2011.

S. Kwon, C. C. Wykoff, D. M. Brown, J. van Hemert, W. Fan, and S. R. Sadda, “Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study,” *British Journal of Ophthalmology*, vol. 102, no. 8, pp. 1066–1071, 2018.

K.-E. Choi, C. Yun, J. Cha, and S.-W. Kim, “OCT angiography features associated with macular edema recurrence after intravitreal bevacizumab treatment in branch retinal vein occlusion,” *Scientific Reports*, vol. 9, no. 1, pp. 1–10, 2019.

J. H. Yoo, J. Ahn, J. Oh, J. Cha, and S.-W. Kim, “Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection,” *British Journal of Ophthalmology*, vol. 101, no. 10, pp. 1334–1339, 2017.

Y. H. Yoon, J. W. Kim, J. Y. Lee et al., “Dexamethasone intravitreal implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion: the multicenter COBALT study,” *Ophthalmologica*, vol. 240, no. 2, pp. 81–89, 2018.